Browsing by Author Karapetis, Christos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 19 of 19
Issue DateTitleAuthor(s)Citation
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabSimes, Robert John; Arena, Sabrina; Bardelli, Alberto; Cutsem, E Van; De Roock, Wendy; Di Nicolantonio, Federica; Frattini, Milo; Jonker, Derek J.; Karapetis, Christos; Khambata-Ford, Shirin; Lamba, Simona; O'Callaghan, Chris; Piessevaux, Hubert; Sartore-Bianchi, Andrea; Siena, Salvatore; Tejpar, Sabine; Tu, D.; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA: The Journal of the American Medical Association, vol.304, 16,pp 1812-1820
2006Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerYip, Desmond; Goldstein, David; Karapetis, Christos; Steer, Christopher B.; Strickland, Andrew; MedicineChemotherapy and radiotherapy for inoperable advanced pancreatic cancer, Cochrane Database of Systematic Reviews, vol.3,(N/A),2006,pp CD002093-CD002093
2010Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive carePavlakis, Nick; Asmis, T; Dueck, D; Gibbs, Peter; Jeffery, M; Jonker, D; Karapetis, Christos; Langer, Christine; O’Callaghan, C; Powell, E; Tu, D.; Whittom, R; Zhu, L; Northern Clinical School: MedicineComorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care, Annals of Oncology, vol.22, 1,pp 118-126
2014Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Pavlakis, Nick; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, J; Tebbutt, Niall; Northern Clinical School: MedicineCurrent opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013, Expert Review of Anticancer Therapy, vol.14, 12, 2014,pp 1477-1493
2013Current opinion on optimal treatment for colorectal cancerPavlakis, Nick; Ackland, Stephen P.; Burge, Matthew; Cunningham, David; Haller, Daniel; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, Jeremy; Sobrero, Alberto; Tebbutt, Niall C; Northern Clinical School: MedicineCurrent opinion on optimal treatment for colorectal cancer, Expert Review of Anticancer Therapy, vol.13, 5, 2013,pp 597-611
2015Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literatureChan, David; Pavlakis, Nick; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, J; Tebbutt, Niall; Northern Clinical School: Medicine; Northern Clinical School: MedicineDoes the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature, PloS One, vol.10, 8, 2015,pp 1-17
2014Final results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidinesFournier, Marion; Gebski, Val; Simes, Robert John; Wilson, Kate; Ferry, David; Gordon, Stuart; Karapetis, Christos; Price, Timothy; Ransom, David; Tebbutt, Niall; Yip, Desmond; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFinal results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines, Annals of Oncology, vol.25, 1, 2014,pp 117-121
2009Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.Pavlakis, Nick; Au, Heather-Jane; et al, various; Jefford, Michael; Karapetis, Christos; Kennecke, Hagen; Koski, Sherryl; Moore, M J; O'Callaghan, Chris; Shapiro, Jeremy; Tu, Dongsheng; Zalcberg, John; Northern Clinical School: MedicineHealth-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial., Journal of Clinical Oncology, vol.27, 11,pp 1822-1828
2012Management of advanced gastric cancerPavlakis, Nick; Price, Timothy; Segelov, Eva; Tebbutt, Niall; Kang, Yoon-Koo; Karapetis, Christos; Shah, Manish; Shapiro, Jeremy; Van Cutsem, E; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreManagement of advanced gastric cancer, Expert Review of Gastroenterology and Hepatology, vol.6, 2, 2012,pp 199-209
2013Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factorsClarke, Stephen; Pavlakis, Nick; Desai, Jayesh; Gibbs, Peter; Karapetis, Christos; Michael, Michael; Pricek, T.J.; Tabernero, Josep; Tebbutt, Niall C; Concord Clinical School: Medicine; Northern Clinical School: MedicineOverview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors, Critical Reviews in Oncology / Hematology (online), vol.85, 2, 2013,pp 121-135
2017Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologistsGooden, Helen; Robotin, Monica; Tattersall, Martin; Guccione, Lisa; Karapetis, Christos; Lambert, Sylvie; Mileshkin, Linda; Schofield, Penelope; Vajdic, Claire M.; Faculty of Nursing & Midwifery; School of Public Health: Public Health; Central Clinical School: MedicinePerceptions of cancer of unknown primary site: a national survey of Australian medical oncologists, Internal Medicine Journal, vol.47, 4, 2017,pp 408-414
2014PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17Simes, Robert John; Daneshmand, Manijeh; et al, Various; Hanson, Jennifer E; Jonker, Derek; Karapetis, Christos; Marginean, Celia; Moore, Malcolm J; OCallghan, Christopher J; Price, Timothy; Tebbutt, Niall C; Zalcberg, John R; School of Public Health: NH&MRC Clinical Trials CentrePIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17, Clinical Cancer Research, vol.20, 3, 2014,pp 744-753
2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialSimes, Robert John; Tebbutt, Niall; Zalcberg, John; Au, Heather-Jane; Australasian Gastrointestinal Interest, Group; Colwell, Bruce; Evans, William K.; Findlay, Brian; Gibbs, Peter; Isogai, Pierre K.; Jonker, Derek J.; Karapetis, Christos; Links, Matthew; Mittman, Nicole; Moore, Malcolm; O'Callaghan, Chris; Siddiqui, Jehan; Tu, D.; Working Group on Economic Analysis of the National Cancer Institute of Canada, Clinical Trials Group; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreProspective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial, Journal of the National Cancer Institute, vol.101, 17, 2009,pp 1182-1192
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Simes, Robert John; Sommeijer, Dirkje; Jonker, Derek J.; Karapetis, Christos; O’CALLAGHAN, Chris; Price, Timothy; Tebbutt, Niall; Tu, Dongsheng; Yip, Desmond; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17, Acta Oncologica, vol.53, 7, 2014,pp 877-884
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838
2014The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsPavlakis, Nick; Chan, D; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, J; Tebbutt, Niall C; Northern Clinical School: MedicineThe role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials, British Journal of Cancer, vol.111, 6, 2014,pp 1122-1131
2016Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Gibbs, Peter; Thavaneswaran, Subotheni; Arnold, Dirk; Burge, Matthew; Haller, Daniel; Karapetis, Christos; Pavlakis, Nick; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreUpdate on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015, Expert Review of Anticancer Therapy, vol.16, 5, 2016,pp 557-571
2016Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Gibbs, Peter; Thavaneswaran, Subotheni; Arnold, Dirk; Burge, Matthew; Haller, Daniel; Karapetis, Christos; Pavlakis, Nick; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreUpdate on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015, Expert Review of Anticancer Therapy, vol.16, 5, 2016,pp 557-571